These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 2081378)

  • 1. The significance of anti-Kell sensitization in pregnancy.
    Mayne KM; Bowell PJ; Pratt GA
    Clin Lab Haematol; 1990; 12(4):379-85. PubMed ID: 2081378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical outcome of non-RhD antibody affected pregnancies in Northern Ireland.
    Chandrasekar A; Morris KG; Tubman TR; Tharma S; McClelland WM
    Ulster Med J; 2001 Nov; 70(2):89-94. PubMed ID: 11795772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Rapid and severe development of fetal hemolytic disease due to anti-Kell antibodies].
    Frère MC; Schaaps JP; Thoumsin H; Retz MC; Rif J; Rigo J; De Cortis T; Lambotte R; Senterre J; Sondag-Thull D
    Rev Med Liege; 1995 Feb; 50(2):63-6. PubMed ID: 7899747
    [No Abstract]   [Full Text] [Related]  

  • 4. Neonatal anti-Kell isoimmune hemolytic disease with spherocytes.
    Merlob P; Reisner SH; Zaizov R
    Pediatr Hematol Oncol; 1986; 3(2):175-8. PubMed ID: 3153228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Kell antibodies in pregnancy].
    Rempen A; Schweppe KW
    Z Geburtshilfe Perinatol; 1983; 187(4):183-90. PubMed ID: 6684844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kell sensitization in pregnancy.
    Caine ME; Mueller-Heubach E
    Am J Obstet Gynecol; 1986 Jan; 154(1):85-90. PubMed ID: 3946507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Fetal death and benign hemolytic disease of the newborn from anti-Cellano alloimmunization: 2 new case reports].
    Rigal D; Juron-Dupraz F; Biggio B; Jouvenceaux A
    Rev Fr Transfus Immunohematol; 1982 Feb; 25(1):101-4. PubMed ID: 7071459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hemolytic disease of the newborn and irregular blood group antibodies in the Netherlands: prevalence and morbidity].
    van Dijk BA; Hirasing RA; Overbeeke MA
    Ned Tijdschr Geneeskd; 1999 Jul; 143(28):1465-9. PubMed ID: 10443262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Haemolytic disease of the newborn--from a mother with anti-Kell, anti-E and anti-Vel anti-erythrocyte alloantibodies].
    Vućinović M; Jadrić H; Karelović D; Roje D; Haspl-Hundrić Z; Hrgović Z; Vućinović Z
    Z Geburtshilfe Neonatol; 2004 Oct; 208(5):197-202. PubMed ID: 15508054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kell alloimmunization, hemolytic disease of the newborn, and perinatal management.
    Wenk RE; Goldstein P; Felix JK
    Obstet Gynecol; 1985 Oct; 66(4):473-6. PubMed ID: 3931011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction of anti-K-mediated hemolytic disease of newborns after the introduction of a matched transfusion policy: A nation-wide policy change evaluation study in the Netherlands.
    Luken JS; Folman CC; Lukens MV; Meekers JH; Ligthart PC; Schonewille H; Zwaginga JJ; Janssen MP; van der Schoot CE; van der Bom JG; de Haas M
    Transfusion; 2021 Mar; 61(3):713-721. PubMed ID: 33528025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The Ko phenotype and fetal-maternal allo-immunization].
    Fourmaintraux A; Vitrac D; Mariette JB; Brunel F
    Arch Fr Pediatr; 1993 Nov; 50(9):779-81. PubMed ID: 8060208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting anti-Kell-mediated hemolytic disease of the fetus and newborn: diagnostic accuracy of laboratory management.
    Slootweg YM; Lindenburg IT; Koelewijn JM; Van Kamp IL; Oepkes D; De Haas M
    Am J Obstet Gynecol; 2018 Oct; 219(4):393.e1-393.e8. PubMed ID: 30063902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Status of Kell incompatibility in a 15-year retrospective study of mother-child serology in clinical records].
    Schönitzer D
    Infusionsther Klin Ernahr; 1987 Apr; 14 Suppl 2():3-9. PubMed ID: 3596796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pregnancy outcome in mothers who develop Kell antibodies.
    Farr V; Gray E
    Scott Med J; 1988 Aug; 33(4):300-3. PubMed ID: 3055288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exchange transfusions and top-up transfusions in neonates with Kell haemolytic disease compared to Rh D haemolytic disease.
    Rath ME; Smits-Wintjens VE; Lindenburg IT; Brand A; van Kamp IL; Oepkes D; Walther FJ; Lopriore E
    Vox Sang; 2011 Apr; 100(3):312-6. PubMed ID: 20849463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maternal Kell blood group alloimmunization.
    Bowman JM; Pollock JM; Manning FA; Harman CR; Menticoglou S
    Obstet Gynecol; 1992 Feb; 79(2):239-44. PubMed ID: 1731292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Perinatal research on feto-maternal anti-Kell immunization].
    Gavriil P; Jauniaux E; Lambermont M; Donner C; Avni FE; Rodesch F
    J Gynecol Obstet Biol Reprod (Paris); 1989; 18(6):761-4. PubMed ID: 2689503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current clinical management of anti-Kell alloimmunization in pregnancy.
    Santiago JC; Ramos-Corpas D; Oyonarte S; Montoya F
    Eur J Obstet Gynecol Reprod Biol; 2008 Feb; 136(2):151-4. PubMed ID: 17481801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythropoietic suppression in fetal anemia because of Kell alloimmunization.
    Vaughan JI; Warwick R; Letsky E; Nicolini U; Rodeck CH; Fisk NM
    Am J Obstet Gynecol; 1994 Jul; 171(1):247-52. PubMed ID: 8030708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.